Tirzepatide
FDA ApprovedA dual GIP/GLP-1 receptor agonist approved globally for type 2 diabetes (Mounjaro), weight management (Zepbound), and obstructive sleep apnea. Extensive clinical trial data from 30+ countries demonstrates significant effects on glycemic control, body weight, and cardiovascular outcomes.
LY3298176 · Mounjaro · Zepbound
38 human studies
- Preclinical
- 10%
- Clinical
- 90%
Based on 42 cited sources
clinically demonstrated · high confidence
Demonstrated effect magnitude — not a recommendation or safety claim.
Research Depth 99 (1A 35 / 1B 25 / 1C 15 / 1D 15 / 1E 9): multiple independent adequately-powered Phase 3 RCT programs (SURMOUNT 35658024 N=2,539; SURPASS 34170647/34672967) with meta-analyses, low risk of bias, total human N in the tens of thousands across 30+ countries, direct population/route/outcome match; preclinical credit capped. Mechanism 100 (2A 40 / 2B 30 / 2C 20 / 2D 10): GIPR + GLP-1R binding with functional and biased-agonism confirmation (Willard 32730231, 5x GIPR potency), full incretin target-to-effect pathway, in-vivo and clinical dose-response. Plausibility 97 (3A 40 / 3B 25 / 3C 20 / 3D 12): full mechanism->surrogate->clinical chain proven for glycemia, weight, OSA (37385275) and HFpEF; coherent with incretin biology; multiple same-class GLP-1RA analogues; minor deduction for multi-indication breadth. Global Coverage 100 (4A 35 / 4B 25 / 4C 25 / 4D 15): robustly reproduced across many independent groups/countries, >100 studies, multi-regulator approval. Community Experience 77 (5A 33 / 5B 18 / 5C 18 / 5D 8): large multi-year population-level use since 2022 approval, highly consistent reports, but recurring GI signal and a thyroid C-cell boxed warning cap 5D. Effectiveness basis clinical (high): SURMOUNT-1 20.9% weight loss at 15mg vs 2.4% placebo (d well above 0.8, far exceeds the ~5% MCID) with head-to-head superiority over semaglutide (SURMOUNT-5 40353578, 20.2% vs 13.7%) and hard patient-relevant outcomes.
Tirzepatide is a “twincretin” - the first dual GIP/GLP-1 receptor agonist designed to harness the full incretin effect.
How It Works (Simplified)
Activates both GIP and GLP-1 receptors simultaneously. GIP accounts for 60-65% of the natural incretin effect, yet was ignored by earlier drugs that only targeted GLP-1.
GIP receptors exist directly on fat cells (adipose tissue), allowing tirzepatide to influence fat metabolism in ways GLP-1-only drugs cannot. Head-to-head trials show ~50% more weight loss than semaglutide.
Both GIP and GLP-1 receptors on pancreatic beta cells work together to enhance insulin secretion in a glucose-dependent manner, minimizing hypoglycemia risk while achieving better HbA1c reduction.
Sends powerful “fullness” signals to the brain through two pathways instead of one. GLP-1R and GIPR both contribute to satiety signaling in the hypothalamus, creating integrated appetite suppression.
Key Research: Willard FS et al. demonstrated 5-fold greater GIPR vs GLP-1R potency with biased signaling favoring cAMP over beta-arrestin. PMID:32730231
Important Limitations
- Gastrointestinal side effects remain common (nausea 12-18%, diarrhea 12-17%), especially during titration
- Thyroid C-cell tumor warning (boxed warning based on rodent studies; clinical relevance in humans uncertain)
- Supply constraints have affected availability since launch; demand continues to exceed supply
- Cost and insurance coverage may limit access for many patients
- Weight regain occurs after discontinuation (SURMOUNT-4 demonstrated this clearly)
- Not studied in combination with other GLP-1 receptor agonists; these should not be combined
- Contraindicated in patients with personal/family history of medullary thyroid carcinoma or MEN2
Reported positives
- Superior weight loss compared to semaglutide frequently reported
- Less nausea than semaglutide cited by switchers
- Significant A1C improvements in diabetic users
- Reduced appetite described as more natural-feeling than other GLP-1s
Reported negatives
- Injection site reactions including redness and itching
- Supply shortages and access difficulties widely reported
- GI side effects still present though often milder than semaglutide
- Fatigue and reduced energy during titration
“r/tirzepatide growing rapidly. Often compared directly to semaglutide in community discussions.”
Self-reported, unverified accounts — not clinical evidence and no substitute for the cited research. Anecdotes are prone to selection bias and placebo effects.
| NCT ID | Title | Peptide | Phase | Status | Completion |
|---|---|---|---|---|---|
| NCT04184622 | SURMOUNT-1 Overweight, Obesity | Tirzepatide | Phase 3 | Completed | Apr 2022 |
| NCT04657003 | SURMOUNT-2 Type 2 Diabetes, Overweight +1 more | Tirzepatide | Phase 3 | Completed | Mar 2023 |
| NCT04657016 | SURMOUNT-3 Obesity, Overweight | Tirzepatide | Phase 3 | Completed | Apr 2023 |
| NCT04660643 | SURMOUNT-4 Obesity, Overweight | Tirzepatide | Phase 3 | Completed | Apr 2023 |
| NCT05822830 | SURMOUNT-5 Obesity, Overweight | Tirzepatide | Phase 3 | Completed | Nov 2024 |
| NCT05412004 | SURMOUNT-OSA Obstructive Sleep Apnea, Obesity | Tirzepatide | Phase 3 | Completed | Mar 2024 |
| NCT03954834 | SURPASS-1 Type 2 Diabetes Mellitus | Tirzepatide | Phase 3 | Completed | Oct 2020 |
| NCT03987919 | SURPASS-2 Type 2 Diabetes | Tirzepatide | Phase 3 | Completed | Jan 2021 |
| NCT03882970 | SURPASS-3 Type 2 Diabetes Mellitus | Tirzepatide | Phase 3 | Completed | Dec 2020 |
| NCT03730662 | SURPASS-4 Type 2 Diabetes Mellitus | Tirzepatide | Phase 3 | Completed | Jan 2021 |
| NCT04039503 | SURPASS-5 Type 2 Diabetes | Tirzepatide | Phase 3 | Completed | Dec 2020 |
| NCT04255433 | SURPASS-CVOT Type 2 Diabetes Mellitus | Tirzepatide | Phase 3 | Completed | Jun 2025 |
| NCT04847557 | SUMMIT (HFpEF) Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF) | Tirzepatide | Phase 3 | Completed | Jul 2024 |
| NCT05556512 | SURMOUNT-MMO Obesity, Overweight | Tirzepatide | Phase 3 | Active | Oct 2027 |
| jRCT2031210504 | SURPASS J-mono | Tirzepatide | Phase 3 | Completed | - |
| jRCT2031210505 | SURPASS J-combo | Tirzepatide | Phase 3 | Completed | - |
| CTR20211515 | China Phase 1 PK | Tirzepatide | Phase 1 | Completed | - |
| NCT07027969 | Metabolic Surgery for Atrial Fibrillation Elimination Atrial Fibrillation, Obesity and Obesity-related Medical Conditions | Tirzepatide | Phase 4 | Not yet recruiting | Dec 2029 |
| NCT07298915 | The Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED) Obesity & Overweight | Tirzepatide | Phase 3 | Not yet recruiting | Dec 2026 |
| NCT07588438 | Efficacy, Safety, and Tolerability of Tirzepatide in Real-World Conditions in Paraguay. Obesity, Diabetes Mellitus, Type 2 | Tirzepatide | Phase 4 | Recruiting | Aug 2027 |
| NCT07554638 | Incretin Therapies in Obesity-related HFpEF Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction +1 more | Tirzepatide | Phase 4 | Not yet recruiting | Apr 2029 |
| NCT07284511 | A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar Type 1 Diabetes, Type 1 Diabetes Mellitus +3 more | Tirzepatide | Phase 2/3 | Recruiting | Jan 2028 |
| NCT07555730 | AI-assisted Multi-domain Lifestyle Versus Tirzepatide for Weight Loss Maintenance in Adults With Type 2 Diabetes (AIM-MAINTAIN) Overweight or Obesity; Type 2 Diabetes, Weight Loss Maintenance | Tirzepatide | Phase 4 | Not yet recruiting | Sep 2028 |
| NCT07257484 | Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors Obesity (Disorder), Breast Cancer | Tirzepatide | Phase 4 | Not yet recruiting | Oct 2027 |
| NCT07218445 | The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity Obesity, Menopause Hot Flashes | Tirzepatide | Phase 4 | Recruiting | Sep 2027 |
| NCT07483801 | DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies Cardiovascular Diseases | Tirzepatide | Phase 4 | Not yet recruiting | Apr 2027 |
| NCT07438444 | A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity Diabetes Mellitus, Type 2, Obesity +1 more | Tirzepatide | Phase 4 | Recruiting | Oct 2027 |
| NCT07481747 | Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1) Obesity, Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities | Tirzepatide | Phase 3 | Recruiting | Feb 2027 |
| NCT07191873 | Tirzepatide in Idiopathic Intracranial Hypertension Trial Idiopathic Intracranial Hypertension (IIH) | Tirzepatide | Phase 4 | Not yet recruiting | Feb 2027 |
Metabolic Surgery for Atrial Fibrillation Elimination
The Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED)
Efficacy, Safety, and Tolerability of Tirzepatide in Real-World Conditions in Paraguay.
Incretin Therapies in Obesity-related HFpEF
A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar
AI-assisted Multi-domain Lifestyle Versus Tirzepatide for Weight Loss Maintenance in Adults With Type 2 Diabetes (AIM-MAINTAIN)
Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors
The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity
DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies
A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)
Tirzepatide in Idiopathic Intracranial Hypertension Trial
Initial titration at 2.5mg weekly. GI side effects (nausea 20-30%) most common during early weeks. Early appetite suppression begins. SURMOUNT-1 showed ~3-4% weight loss in first 4 weeks.
PMID:35658024Dose escalation through 5mg, 7.5mg toward maintenance doses. GI tolerability generally improves. Weight loss accelerates to 6-10%. Blood glucose significantly improved in diabetes trials.
PMID:35658024Approaching maximum dose (10mg, 12.5mg, or 15mg). SURMOUNT-1 showed 15-18% weight loss by week 20. HbA1c reductions of 2.0%+ typical at highest doses. Substantial metabolic improvements.
PMID:35658024Near-maximum effects achieved. SURMOUNT-1 showed 20.9% mean weight loss at 15mg by 72 weeks. Significant improvements in cardiovascular risk factors, liver enzymes, and inflammatory markers.
PMID:35658024Weight loss typically plateaus at a new set point with continued use. SURMOUNT-1 showed weight loss maintained through 72 weeks. Like other GLP-1 therapies, discontinuation is expected to result in weight regain.
PMID:35658024Research-based observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Good Signs (6 indicators)
Warning Signs (5 indicators)
Bad Signs (7 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
AOD-9604
CompatibleAOD-9604 is a GH fragment without diabetogenic effects. Different mechanisms (incretin vs lipolysis). Limited interaction data available.
Tesamorelin
CautionBoth affect metabolic parameters. Tesamorelin increases GH which may affect glucose homeostasis. Monitor carefully in diabetic patients.
Ipamorelin
CautionGH secretagogues may affect glucose metabolism. Monitor glucose parameters if considering combination.
MK-677
CautionMK-677 increases GH and IGF-1, which can impair glucose tolerance. May counteract tirzepatide's glycemic benefits. Monitor closely.
Semaglutide
AvoidDo not combine. Both are incretin-based therapies with overlapping mechanisms (tirzepatide includes GLP-1 agonism). Combination provides no additional benefit with increased adverse event risk.
Liraglutide
AvoidDo not combine. Tirzepatide already includes GLP-1 receptor agonism. Adding another GLP-1RA would be redundant and increase adverse event risk.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Tirzepatide
Related Peptides
5-Amino-1MQ
5-Amino-1-Methylquinolinium · NNMT Inhibitor
A small molecule NNMT inhibitor studied for metabolic effects in animal models. No human clinical trials have been conducted. Increases NAD+ levels in adipose tissue in preclinical studies.
Amycretin
NNC0487-0111 · Oral Amycretin · Subcutaneous Amycretin
A novel single-molecule dual GLP-1/amylin receptor agonist developed by Novo Nordisk. Unlike CagriSema (a fixed-dose combination), amycretin is a unified peptide that activates both pathways. Phase 1 trials showed superior weight loss signals versus semaglutide, with both oral and subcutaneous formulations in development.
AOD-9604
Anti-Obesity Drug 9604 · Tyr-hGH Fragment 177-191 · hGH Fragment 176-191
A modified fragment of human growth hormone (amino acids 176-191 with N-terminal tyrosine) studied for fat loss. Clinical development discontinued after Phase 2b/3 trials failed to show efficacy in 536 subjects. Now prohibited by WADA and excluded from FDA compounding.
Cagrilintide
AM833 · NN9838
A long-acting amylin analog developed by Novo Nordisk for weight management. Studied in Phase 3 trials as CagriSema (combination with semaglutide). The Phase 3 REDEFINE 1 trial showed -20.4% weight loss with cagrilintide-semaglutide versus -3.0% with placebo at 68 weeks.
CagriSema
Cagrilintide-Semaglutide · NNC0174-0833
A fixed-dose combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) for chronic weight management. Phase 3 REDEFINE trials demonstrate 20-23% weight loss at 68 weeks. NDA submitted to FDA December 2025. First GLP-1/amylin combination therapy.
CT-388
RG-6912
A dual GLP-1/GIP receptor agonist (INN enicepatide; also RO7795068) acquired by Roche through the $2.7 billion Carmot Therapeutics acquisition in 2024. The published Phase 1 trial (NCT04838405) showed 4.7-8.0% mean weight loss vs 0.5% placebo over 4 weeks; a more widely reported ~18.8% placebo-adjusted figure at 24 weeks comes from an unpublished Phase 1 extension reported via press release. Phase 2 obesity and T2D trials are completed or ongoing and Phase 3 began in 2026, positioning it as a competitive obesity therapeutic with a mechanism similar to tirzepatide.
Related Content
Semaglutide
Metabolic · high evidence
Retatrutide
Metabolic · high evidence
What is Mounjaro?
An introduction to Mounjaro, the brand name for tirzepatide ...
What is Tirzepatide?
An introduction to tirzepatide, a dual GIP/GLP-1 receptor ag...
5-Amino-1MQ vs Tirzepatide
View side-by-side analysis
Amycretin vs Tirzepatide
View side-by-side analysis